Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med
Locked in a heated battle for I/O supremacy, Merck and Bristol have readily engaged in proxy battles for new indications, tag-teaming their blockbusters with other meds to get a leg up. Now, after already scoring a combo win with another TKI inhibitor in kidney cancer, Merck is holding up promising data for another Keytruda pairing.
A combination of Keytruda and Eisai’s TKI inhibitor Lenvima significantly extended the time patients lived without their disease getting worse in a head-to-head matchup with TKI drug sunitinib, the standard of care in first-line advanced renal cell carinoma, according to data presented Saturday at the virtual ASCO GU meeting.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.